Immuno-oncology | American Association for Cancer Research Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Immuno-oncology

Studies that investigate the immune system, its interactions with tumor cells, and opportunities to enhance the body's natural defenses against cancer

SUBMIT TO JOURNAL
Latest in Immuno-oncology
May 20 2024
Multi-omics analysis of a fecal microbiota transplantation trial identifies novel aspects of acute graft-versus-host disease pathogenesis
Armin Rashidi, Maryam Ebadi et al.
Acute graft-versus-host disease (aGVHD) is a major complication of allogeneic hematopoietic cell transplantation (alloHCT) associated with gut microbiota disruptions. However, whether therapeutic microbiota modulation prevents aGVHD is unknown. We conducted a randomized, placebo-controlled trial of third-party fecal ...
May 16 2024
The FKBP51s Splice Isoform Predicts Unfavorable Prognosis in Patients with Glioblastoma
Carolina Giordano, Laura Marrone et al.
The primary treatment for glioblastoma (GBM) is removing the tumor mass as defined by MRI. However, MRI has limited diagnostic and predictive value. Tumor-associated macrophages (TAM) are abundant in GBM tumor microenvironment (TME) and are found in peripheral blood (PB). FKBP51 expression, with its canonical and spliced ...
May 15 2024
HDAC6 inhibition releases HR23B to activate proteasomes, expand the tumor immunopeptidome and amplify T-cell antimyeloma activity
Priyanka S. Rana, James J. Ignatz-Hoover et al.
Proteasomes degrade intracellular proteins to generate antigenic peptides that are recognized by the adaptive immune system and promote anticancer immunity. However, tumors subvert the antigen presentation machinery to escape immunosurveillance. We hypothesized that proteasome activation could concomitantly increase ...
May 13 2024
Exercise-induced β2-adrenergic Receptor Activation Enhances the Antileukemic Activity of Expanded γδ T-Cells via DNAM-1 Upregulation and PVR/Nectin-2 Recognition
Forrest L. Baker, Kyle A. Smith et al.
Exercise mobilizes cytotoxic lymphocytes to blood which may allow superior cell products to be harvested and manufactured for cancer therapy. Gamma-Delta (γδ) T-cells have shown promise for treating solid tumors, but there is a need to increase their potency against hematologic malignancies. Here, we show that human γδ ...
May 10 2024
Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with combined SOS1 and MEK Inhibition for Improved Immunotherapy Response
Robert J Norgard, Pratha Budhani et al.
KRAS inhibitors have demonstrated exciting pre-clinical and clinical responses, although resistance occurs rapidly. Here, we investigate the effects of KRAS-targeting therapies on the tumor microenvironment using a library of KRASG12D, p53 mutant, murine PDAC-derived cell lines (KPCY) to leverage immune-oncology ...
May 09 2024
Transcriptome deconvolution reveals absence of cancer cell expression signature in immune checkpoint blockade response
Yu Amanda Guo, Tanmay Kulshrestha et al.
Immune-checkpoint therapy (ICB) has conferred significant and durable clinical benefit to some cancer patients. However, most patients do not respond to ICB, and reliable biomarkers of ICB response are needed to improve patient stratification. Here, we performed a transcriptome-wide meta-analysis across 1,486 tumors from ...
May 08 2024
B7-H3-Targeting Chimeric Antigen Receptors Epstein Barr Virus Specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3 Positive Solid Tumors
Siok Ping Yeo, Lindsay Kua et al.
Encouraged by our observations of pronounced B7-H3 protein over-expression in many human solid tumors compared to healthy tissues, we focused on targeting B7-H3 with CAR T cells. We utilized a nanobody as the t B7-H3 targeting domain in our CAR construct to circumvent the stability issues associated with scFv-based ...
May 08 2024
LYVE-1-expressing macrophages modulate the hyaluronan-containing extracellular matrix in the mammary stroma and contribute to mammary tumor growth
Alexis K. Elfstrum, Annisa H. Rumahorbo et al.
Macrophages represent a heterogeneous myeloid population with diverse functions in normal tissues and tumors. While macrophages expressing the cell surface marker lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) have been identified in stromal regions of the normal mammary gland and in the peri-tumoral stroma, ...
May 06 2024
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target across Human Malignancies
Carly D Miller, John R. Lozada et al.
May 06 2024
Efficacy and safety of atezolizumab and bevacizumab in appendiceal adenocarcinoma
Nicholas J. Hornstein, Mohammad A. Zeineddine et al.
View all Immuno-oncology articles

Topics in Immuno-oncology

AACR Journals

 

 

  • Copyright © 2023 by the American Association for Cancer Research.
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept